Mesenchymal stem cells (MSCs) are now known to display not only stem cell multipotency, but also robust anti-inflammatory and regenerative properties. After widespread in-vitro and in-vivo preclinical testing, autologous and allogeneic MSCs have been applied in a range of immune mediated conditions, including graft versus host disease, Crohn’s disease, multiple sclerosis, refractory systemic lupus erythematosus and systemic sclerosis. Current data suggests that MSCs may not only replace diseased tissues, but also exert several trophic, regenerative and anti-inflammatory effects. While the clinical outcome in case reports and phase I-II trials seems occasionally striking, these limited results point to the need to perform controlled multicenter trials.
Future advances from stem cell science can be expected to pinpoint significant MSC subpopulations and/or stem cell markers for improved regenerative or immunoregulatory properties. We are waiting for government to fund such trials, mean while needy patients who do not have any other therapeutic option left and who are not satisfied with the standard treatments available may avail this stem cell therapy for autoimmune diseases under experimental therapy program on case to case basis only.You can contact us with your medical information to know if you are suitable for this program.
Stem cell therapy is a innovative medical procedure which needs more clinical trials to document its safety & efficacy in larger population base before it is made available for day to day standard medical practice. At present it is available on case to case basis for selected patients under controlled delivery system only.